Lachlan MacKinnon
CEO/Co-Founder
Replay
Replay is a genome writing company utilizing high payload herpes simplex virus (HSV) technology to deliver up to 150kb of DNA for gene therapies targeting complex diseases. The company addresses the limitations of current genomic medicine by enabling the writing and installation of large genetic constructs, facilitating the treatment of conditions affecting the skin, eye, brain, and muscle.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$83.4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current gene therapy approaches are limited by the size of DNA that can be effectively delivered, restricting their ability to address complex diseases requiring large genetic constructs or multiple genes. Traditional methods struggle to deliver the necessary genetic material to target tissues in vivo or to engineer cells ex vivo for cell therapies.
Solution
Replay leverages its high-payload herpes simplex virus (HSV) technology to overcome the limitations of existing gene therapies. The company's platform enables the delivery of up to 150kb of DNA, facilitating the introduction of large genes, genomic genes, or multiple genes into target cells. This capability allows for the incorporation of complex regulatory elements and the potential to address polygenic diseases. Replay's HSV technology can be used both in vivo for direct delivery to tissues and ex vivo for engineering autologous, allogeneic, and iPSC-derived cell therapies. The platform offers an alternative to multiplex editing by enabling the writing and installation of large genetic constructs, and it holds potential for multiplexing CARs and TCRs in cell therapies.
Target Audience
Replay's primary customers are gene therapy developers and researchers focused on complex diseases affecting the skin, eye, brain, and muscle, as well as companies developing cell therapies.
Features
- High-payload HSV vector capable of delivering up to 150kb of DNA
- In vivo and ex vivo delivery capabilities
- Ability to deliver large genes, genomic genes, or multiple genes
- Facilitates the incorporation of complex regulatory elements
- Potential to address polygenic diseases
- Enables writing and installation of large constructs to replace multiplex editing
- Potential for multiplexing CARs and TCRs in cell therapies